 |
 |
|
|
||||||
|
| The symptoms of OAB can disrupt your patients’ lives in numerous ways. Both “wet” and “dry” OAB patients fear they may leak, and this fear can lead to inconvenient or uncomfortable coping behaviors like bathroom mapping and use of a diaper or pad.3
To devise an effective treatment for your OAB patients, consider the goals of and various approaches to OAB treatment. |
| vesicarerx.com |
| Learn more about VESIcare with an interactive online experience. Click here. |
| Patient Resources |
| The VESIcare.com website for consumers contains a bladder checklist, a bladder dairy and other important information to help patients gain a better understanding of overactive bladder. The Vantage ProgramSM provides valuable information and exclusive savings for your patients. Click here to learn more. |
| Important Safety Information VESIcare tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily. As with other anticholinergic agents, VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. As with other anticholinergic agents, VESIcare should be administered with caution to patients with bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal or hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended. In placebo-controlled studies, the most common adverse events reported by patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and dyspepsia (1.4%, 3.9%, 1.0%) with VESIcare 5 mg, 10 mg, and placebo, respectively. The overall rate of serious adverse events was 2%. For the 10-mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction, and one intestinal obstruction). For the 5-mg dose, one case of angioneurotic edema was reported. |
|
Complete Prescribing Information for VESIcare |
|
|
VESIcare is a registered trademark of Astellas Pharma Inc. This site is intended for US residents only. © 2005-2010 Astellas Pharma US, Inc. and The GlaxoSmithKline Group of Companies All rights reserved. |
| Legal Notices | Privacy Statement | Contact Us | Site Map |